A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Palbociclib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 28 Jan 2019 Status changed from active, no longer recruiting to completed.
- 28 Jan 2019 Results evaluating tolerability and safety of ibrutinib plus palbociclib in previously treated mantle cell lymphoma patients published in the Blood
- 26 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 May 2017.